BidaskClub upgraded shares of Icon (NASDAQ:ICLR) from a hold rating to a buy rating in a research note issued to investors on Friday, BidAskClub reports.

Several other equities research analysts have also recently commented on ICLR. UBS Group set a $160.00 target price on Icon and gave the stock a hold rating in a report on Friday, October 25th. Zacks Investment Research raised Icon from a hold rating to a buy rating and set a $191.00 target price on the stock in a report on Wednesday, December 25th. Credit Suisse Group reaffirmed a buy rating and issued a $160.00 price target on shares of Icon in a report on Monday, October 28th. Citigroup began coverage on Icon in a report on Monday, January 6th. They issued a neutral rating and a $185.00 price target on the stock. Finally, Wells Fargo & Co began coverage on Icon in a report on Tuesday, January 7th. They issued an equal weight rating and a $180.00 price target on the stock. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $169.56.

Shares of NASDAQ:ICLR opened at $175.78 on Friday. Icon has a 12 month low of $127.58 and a 12 month high of $176.30. The stock has a market cap of $9.49 billion, a price-to-earnings ratio of 26.39, a PEG ratio of 2.12 and a beta of 0.70. The stock’s 50 day moving average price is $167.92 and its 200 day moving average price is $155.99. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.03 and a quick ratio of 2.03.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $1.74 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.74. Icon had a return on equity of 24.86% and a net margin of 13.16%. The firm had revenue of $710.40 million for the quarter, compared to analysts’ expectations of $709.75 million. During the same quarter in the previous year, the company earned $1.54 earnings per share. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, sell-side analysts expect that Icon will post 6.89 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. raised its stake in Icon by 6,790.7% during the 2nd quarter. Invesco Ltd. now owns 536,782 shares of the medical research company’s stock valued at $82,648,000 after purchasing an additional 528,992 shares during the period. Comgest Global Investors S.A.S. raised its stake in Icon by 51.7% during the 3rd quarter. Comgest Global Investors S.A.S. now owns 1,524,903 shares of the medical research company’s stock valued at $224,680,000 after purchasing an additional 519,534 shares during the period. SPF Beheer BV acquired a new stake in Icon during the 3rd quarter valued at $76,360,000. WCM Investment Management LLC raised its stake in Icon by 6.0% during the 3rd quarter. WCM Investment Management LLC now owns 3,595,030 shares of the medical research company’s stock valued at $529,691,000 after purchasing an additional 203,734 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its stake in Icon by 5.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,391,700 shares of the medical research company’s stock valued at $205,052,000 after purchasing an additional 70,921 shares during the period. 85.82% of the stock is currently owned by institutional investors.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: 52-Week High/Low Prices For Stock Selection

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.